UPB · Insider Trading
Upstream Bio, Inc. Common Stock
Every open-market purchase and sale reported by UPB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Everett Rand Sutherland | Chief Executive Officer | Sell | −2,095 | −$11.50K |
| 2026-09-17 | Aaron Deykin | Chief Medical Officer | Sell | −895 | −$4.91K |
| 2026-09-17 | Adam Houghton | Chief Business Officer | Sell | −700 | −$3.84K |
| 2026-09-17 | Allison Ambrose | General Counsel | Sell | −485 | −$2.66K |
| 2026-09-17 | Michael Gray | CFO and COO | Sell | −853 | −$4.68K |
| 2026-06-17 | Michael Gray | CFO and COO | Sell | −853 | −$5.20K |
| 2026-06-17 | Aaron Deykin | Chief Medical Officer | Sell | −895 | −$5.46K |
| 2026-06-17 | Everett Rand Sutherland | Chief Executive Officer | Sell | −2,095 | −$12.78K |
| 2026-06-17 | Adam Houghton | Chief Business Officer | Sell | −700 | −$4.27K |
| 2026-06-17 | Allison Ambrose | General Counsel | Sell | −477 | −$2.91K |
| 2026-06-11 | Marcella K. Ruddy | Director | A | +17,096 deriv. | — |
| 2026-06-11 | Harold Edward Fleming | Director | A | +17,096 deriv. | — |
| 2026-06-11 | Ronald C Renaud JR | Director | A | +17,096 deriv. | — |
| 2026-06-11 | Daniella Beckman | Director | A | +17,096 deriv. | — |
| 2026-06-11 | Erez Chimovits | Director | A | +17,096 deriv. | — |
| 2026-06-11 | Liam Ratcliffe | Director | A | +17,096 deriv. | — |
| 2026-03-17 | Adam Houghton | Chief Business Officer | Sell | −699 | −$6.49K |
| 2026-03-17 | Everett Rand Sutherland | Chief Executive Officer | Sell | −2,093 | −$19.44K |
| 2026-03-17 | Aaron Deykin | Chief Medical Officer | Sell | −894 | −$8.31K |
| 2026-03-17 | Allison Ambrose | General Counsel | Sell | −475 | −$4.41K |
| 2026-03-17 | Michael Gray | CFO and COO | Sell | −852 | −$7.92K |
| 2026-01-06 | Everett Rand Sutherland | Chief Executive Officer | A | +75,000 | — |
| 2026-01-06 | Aaron Deykin | Chief Medical Officer | A | +32,000 | — |
| 2026-01-06 | Adam Houghton | Chief Business Officer | A | +25,000 | — |
| 2026-01-06 | Allison Ambrose | General Counsel | A | +17,000 | — |
| 2026-01-06 | Michael Gray | CFO and COO | A | +30,500 | — |
| 2025-06-12 | Erez Chimovits | Director | A | +17,096 deriv. | — |
| 2025-06-12 | Harold Edward Fleming | Director | A | +17,096 deriv. | — |
| 2025-06-12 | Marcella K. Ruddy | Director | A | +17,096 deriv. | — |
| 2025-06-12 | Liam Ratcliffe | Director | A | +17,096 deriv. | — |
| 2025-06-12 | Ronald C Renaud JR | Director | A | +17,096 deriv. | — |
| 2025-06-12 | Daniella Beckman | Director | A | +17,096 deriv. | — |
| 2025-02-07 | Allison Ambrose | General Counsel | A | +25,000 deriv. | — |
| 2025-02-07 | Michael Gray | CFO and COO | A | +195,000 deriv. | — |
| 2025-02-07 | Aaron Deykin | Chief Medical Officer | A | +165,000 deriv. | — |
| 2025-02-07 | Adam Houghton | Chief Business Officer | A | +140,000 deriv. | — |
| 2025-02-07 | Everett Rand Sutherland | Chief Executive Officer | A | +500,000 deriv. | — |
| 2024-12-17 | Allison Ambrose | General Counsel | A | +100,000 deriv. | — |
| 2024-10-17 | Erez Chimovits | Director | MIXED | +4,434,789 | +$14.03M |
| 2024-10-17 | AI Upstream LLC | 10%+ Owner | MIXED | +27,472,050 | +$99.88M |
| 2024-10-17 | OrbiMed Advisors Israel II Ltd | Director | MIXED | +17,739,156 | +$56.10M |
| 2024-10-15 | Daniella Beckman | Director | A | +34,681 deriv. | — |
| 2024-10-15 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | C | +894,733 | — |
| 2024-10-15 | Ronald C Renaud JR | Director | A | +17,096 deriv. | — |
| 2024-10-15 | Erez Chimovits | Director | A | +17,096 deriv. | — |
| 2024-10-15 | Harold Edward Fleming | Director | A | +17,096 deriv. | — |
| 2024-10-15 | Marcella K. Ruddy | Director | A | +17,096 deriv. | — |
| 2024-10-15 | Liam Ratcliffe | Director | A | +17,096 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Erez Chimovits | Director | 973,716 | $2.86M |
| Everett Rand Sutherland | Chief Executive Officer | 68,717 | $201.68K |
| Aaron Deykin | Chief Medical Officer | 32,302 | $94.81K |
| Michael Gray | CFO and COO | 27,942 | $82.01K |
| Adam Houghton | Chief Business Officer | 22,901 | $67.21K |
| Allison Ambrose | General Counsel | 15,563 | $45.68K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the UPB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.